Editorials
PSM Executive Director Shabbir Imber Safdar released the following statement in response to news that Hims & Hers is now compounding pill versions of a newly approved GLP-1 weight-loss drug.
This post outlines practical steps Congress should take to strengthen pharmaceutical border security, reinforce regulatory oversight, and protect patients.
Federally-registered compounding facilities stopped making tirzepatide on May 22. This transition is significant for patients, and we at PSM think there are four things you should be watching for.
Articles in Endpoints News and the Houston Chronicle raise questions about the regulatory process for 503B compounding facilities.
Partnership for Safe Medicines released the following statement in response to the advertisement that lifestyle brand Hims & Hers released ahead of the Super Bowl to sell unregulated compounded weight loss drugs